Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

NCT05196386 | Completed

• 2 other identifiers: 2019/0025/HP2019-A00515-52
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction. The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department. The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Conditions

Non-cancerous Pain; Opioid Use

Outcome Measures

Primary Outcomes (1)

• Total duration of opioid treatment

  6 months

Secondary Outcomes (2)

• Rate of patients exceeding 28 days of cumulative duration of treatment

  6 months

• Rate of patients exceeding 90 days of cumulative duration of treatment

  6 months

Study Arms (2)

Patient with targeted pharmaceutical interview

EXPERIMENTAL

Specific information about treatment delivered by pharmacist

Behavioral: Admission conciliation interview; Behavioral: Discharge conciliation interview; Behavioral: Targeted pharmaceutical interview

Patient without targeted pharmaceutical interview

OTHER

No Specific information about treatment delivered by pharmacist

Behavioral: Admission conciliation interview; Behavioral: Discharge conciliation interview

Interventions

Admission conciliation interview BEHAVIORAL

Previous treatment conciliation at hospital admission

Patient with targeted pharmaceutical interview; Patient without targeted pharmaceutical interview

Discharge conciliation interview BEHAVIORAL

Allocated treatment during hospital stay

Patient with targeted pharmaceutical interview; Patient without targeted pharmaceutical interview

Targeted pharmaceutical interview BEHAVIORAL

Specific information about treatment delivered by pharmacist

Patient with targeted pharmaceutical interview

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 and \< 75 years old when entering the rheumatology department
• Hospitalization in the rheumatology department
• Patient with acute non-traumatic musculoskeletal disease
• Patient not taking grade III opioid treatment
• Patient affiliated to a social security scheme
• Patient having read and understood the information letter and signed the consent form
• Patient present on a day which the pharmacy intern is present

You may not qualify if:

• Patient does not understand French
• Patient with Current or past opioid addiction
• Person deprived of liberty by administrative or judicial decision

Sponsors & Collaborators

• University Hospital, Rouen: lead

Study Sites (1)

Rouen University Hospital

Rouen, France

Location

Study Officials

• Olivier VITTECOQ, Pr

  University Hospital, Rouen

  PRINCIPAL INVESTIGATOR

• Remi VARIN, Pr

  University Hospital, Rouen

  PRINCIPAL INVESTIGATOR

• Catherine CHENAILLER, Dr

  University Hospital, Rouen

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 4, 2020
• First Posted: January 19, 2022
• Study Start: August 6, 2020
• Primary Completion: August 28, 2023
• Study Completion: August 28, 2023
• Last Updated: June 5, 2026

Record last verified: 2025-09

Locations

FR (1)